Covaxin
Covaxin News
Health
Completing fight against COVID in India: Why adults should not ignore precautionary dose
The mortality rate because of COVID has come down but, we should not go away from taking the necessary precautions
Health
Biological E Limited delivers 10 crore doses of Corbevax to Centre
Corbevax is expected to be available as a booster dose on the CoWIN App in public and private vaccination centres from 12 August
COVID-19: Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country
Health
Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years
If approved by the government, this would be the first time a booster dose of a COVID vaccine different from the one used for primary vaccination would be allowed in the country
Health
Linking COVID-19 vaccine with Monkeypox: Busting the myths
The virus has been named Monkeypox because initially it was detected in a monkey
India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre
Minister of State for Health Bharati Pravin Pawar said as on 19 July, 2022, a total of 200.34 crore COVID-19 vaccine doses have been administered to beneficiaries above 12 years of age in the country
200 crore vaccinations: How India under Narendra Modi scripted Covid success story
The country crossed a record 200 crore Covid-19 vaccinations on 17 July 2022 within barely 18 months of launching this exercise on 16 January last year
Over 57% seniors faced mental health issues during COVID-19, 59% say government managed pandemic well
The fear of COVID-19 infection was the most prevalent factor that contributed to the rising mental health concerns among seniors
Vaxxed to the max: A look at India's COVID vaccination drive that is set to overtake US, Europe and Canada combined
As per official data, a total of 1,96,24,21,213 doses have been administered so far across the country, which is set to cross the combined doses of the United States, Europe and Canada
Health
Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity
Health
As COVID-19 cases rise, vaccines play vital role to prevent mass hospitalization, adverse outcomes
Vaccines play a crucial role in preventing infection, hospitalizations, and adverse outcomes which cause deaths
Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June
In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin
Health
In 15-18 years age group, over 80% got first dose of COVID vaccine, says Mandaviya
India began inoculating those in the age group of 15-18 years from 3 January and so far 5.92 crore beneficiaries in this age group have been given the first dose
Health
COVID-19 is not over yet and why vaccination is important for better fighting chance
Vaccination is a worldwide accepted strategy to encounter the COVID-19 as soon as possible with the vaccines approved by their public health authorities
COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
The company has already conducted trials in the age group of 2-18 for two doses of Covaxin
Health
Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA
Following an inspection of the Bharat Biotech premises on 14 March for Covaxin's EUL, WHO announced the suspension of the vaccine's supply owing to deficiencies in good manufacturing practices
Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12
The DCGI has also given restricted emergency use authorisation to Covaxin, manufactured by Hyderabad based pharmaceutical company - Bharat Biotech, for children between 6 and 12 years
DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years
Bharat Biotech has been asked to submit safety data alongwith the data on adverse event with due analysis, every 15 days for the first two months and after that monthly data for up to five months
Adar Poonawalla warns against return to business-as-usual approach
He pointed out that there is rising vaccine fatigue among the public as the main reason for the low off-take of the vaccines even after the firm has massively slashed the price from Rs 600 to Rs 225 a dose
Health
DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group
India is currently administering two COVID-19 vaccines for children above 12